The ONE AI Stock to own now. (It’s not Nvidia.)

Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …

Christina Rossi Biography and Net Worth

Insider of Blueprint Medicines

Christy has more than 20 years of global pharmaceutical and biotechnology experience. Since April 2022, Christy has served as Chief Operating Officer of Blueprint Medicines. Previously, she served as Chief Commercial Officer from October 2018 to April 2022 and has overseen the commercial launches of AYVAKIT® (avapritinib) and GAVRETO® (pralsetinib) across multiple indications and geographies, including the creation of commercial infrastructure and successful market access efforts in the U.S. and Europe. Prior to joining Blueprint Medicines, she served as the Multiple Sclerosis (MS) Business Unit Head, North America, at Sanofi Genzyme. In this role, she oversaw all aspects of the financial performance of Sanofi Genzyme’s MS franchise and increased market share for existing products, led the launch of new therapies and optimized operations to accelerate patient access. Previously, Christy served as Vice President, MS Sales, and Vice President, MS Patient and Provider Services, at Sanofi Genzyme. Prior to joining Sanofi Genzyme, she held various roles at Biogen Inc., including Head, Commercial Strategy for Eidetica Biopharma GmbH, Biogen’s biosimilar-focused venture, and U.S. Brand Leader for TYSABRI® (natalizumab). In addition, she consulted in the healthcare practice at the Boston Consulting Group. Christy holds a B.S. in biology, cum laude, from Duke University and an M.B.A. from Harvard Business School. She currently serves as an independent director on the board of Xilio Therapeutics and is a member of the compensation committee.

What is Christina Rossi's net worth?: The estimated net worth of Christina Rossi is at least $6.75 million as of March 7th, 2024. Ms. Rossi owns 64,306 shares of Blueprint Medicines stock worth more than $6,749,558 as of May 20th. This net worth estimate does not reflect any other investments that Ms. Rossi may own. Learn More about Christina Rossi's net worth.
How do I contact Christina Rossi?: The corporate mailing address for Ms. Rossi and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on Christina Rossi's contact information.
Has Christina Rossi been buying or selling shares of Blueprint Medicines?: Christina Rossi has not been actively trading shares of Blueprint Medicines within the last three months. Most recently, Christina Rossi sold 6,070 shares of the business's stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $90.69, for a transaction totalling $550,488.30. Following the completion of the sale, the chief operating officer now directly owns 64,306 shares of the company's stock, valued at $5,831,911.14. Learn More on Christina Rossi's trading history.
Who are Blueprint Medicines' active insiders?: Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (COO), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?: In the last twelve months, insiders at the biotechnology company sold shares 26 times. They sold a total of 184,377 shares worth more than $14,954,930.51. The most recent insider tranaction occured on May, 2nd when CFO Michael Landsittel sold 10,000 shares worth more than $1,050,000.00. Insiders at Blueprint Medicines own 3.9% of the company. Learn More about insider trades at Blueprint Medicines.
Information on this page was last updated on 5/2/2024.

Christina Rossi Insider Trading History at Blueprint Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2024	Sell	6,070	$90.69	$550,488.30	64,306
3/6/2023	Sell	3,059	$45.67	$139,704.53	55,376
11/3/2022	Sell	533	$45.24	$24,112.92	43,435
11/3/2020	Sell	345	$99.69	$34,393.05	20,020

Christina Rossi Buying and Selling Activity at Blueprint Medicines

Blueprint Medicines Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $104.96

$103.23

$107.17

50 Day Range

MA: $94.50

$85.18

$108.78

2 Week Range

Now: $104.96

$43.89

$111.02

Volume

415,500 shs

Average Volume

754,891 shs

Market Capitalization

$6.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65

Protect Your Bank Account Before It’s Too Late

From Weiss Ratings | Ad

For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …

Stop right now and do these 3 things to protect yourself